StreetInsider.com News Articles

Lexeo phase I/II data for Friedreich ataxia gene therapy published

Wed, 17 Jun 2026 16:01:46 -0400

Lexeo Therapeutics (Nasdaq: LXEO) announced that Phase I/II study results for its LX2006 gene therapy in Friedreich ataxia (FA) have been published in JAMA Cardiology.

The publication combines data from 17 participants across two independent studies: nine from a Weill Cornell Medicine study funded by the National Heart, Lung, and Blood Institute, and eight from Lexeo's own SUNRISE-FA study. Patients received a one-hour intravenous infusion of LX2006 and were evaluated over periods ranging from 6 to 36 months across three dose cohorts.

Among participants with abnormal baseline left ventricular mass index (LVMI) in mid- and high-dose cohorts, the data showed a 28%

Lexeo phase I/II data for Friedreich ataxia gene therapy published

Wed, 17 Jun 2026 16:01:46 -0400

Lexeo Therapeutics (Nasdaq: LXEO) announced that Phase I/II study results for its LX2006 gene therapy in Friedreich ataxia (FA) have been published in JAMA Cardiology.

Among participants with abnormal baseline left ventricular mass index (LVMI) in mid- and high-dose cohorts, the data showed a 28%

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Wed, 17 Jun 2026 16:01:00 -0400

Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies

SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in Q2 2026 with topline data expected in 2H 2027

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that key results from Phase I/II studies of LX2006 gene therapy in Friedreich ataxia (FA) have been published in the Journal

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Wed, 17 Jun 2026 16:01:00 -0400

Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies

SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in Q2 2026 with topline data expected in 2H 2027

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Wed, 17 Jun 2026 16:01:00 -0400

Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies

SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in Q2 2026 with topline data expected in 2H 2027

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Wed, 17 Jun 2026 16:01:00 -0400

Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies

SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in Q2 2026 with topline data expected in 2H 2027

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Wed, 17 Jun 2026 16:01:00 -0400

Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies

SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in Q2 2026 with topline data expected in 2H 2027

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Wed, 17 Jun 2026 16:01:00 -0400

Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies

SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in Q2 2026 with topline data expected in 2H 2027

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Wed, 17 Jun 2026 16:01:00 -0400

Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies

SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in Q2 2026 with topline data expected in 2H 2027

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Wed, 17 Jun 2026 16:01:00 -0400

Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies

SUNRISE-FA 2 pivotal study for LX2006 on track to initiate in Q2 2026 with topline data expected in 2H 2027

Form 8-K Lexeo Therapeutics, Inc. For: Jun 15

Mon, 15 Jun 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260615/26644141.html

Form 8-K Lexeo Therapeutics, Inc. For: Jun 15

Mon, 15 Jun 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260615/26644141.html

Lexeo finalizes pivotal trial design for gene therapy in heart condition

Mon, 15 Jun 2026 07:01:08 -0400

Lexeo Therapeutics Inc. (NASDAQ: LXEO) announced it has completed the protocol and statistical analysis plan for its SUNRISE-FA 2 pivotal trial of gene therapy candidate LX2006 for Friedreich ataxia cardiomyopathy, according to a company statement.

The open-label study will enroll 13 participants aged 16 years and older to receive a single intravenous dose of LX2006, compared with 13 untreated control participants. The primary endpoint measures left ventricular mass index through cardiac magnetic resonance imaging, with efficacy results expected at six months post-treatment.

Participants will have abnormal baseline left ventricular mass index, defined as at least two standard deviations above normal. The study

Lexeo finalizes pivotal trial design for gene therapy in heart condition

Mon, 15 Jun 2026 07:01:08 -0400

Participants will have abnormal baseline left ventricular mass index, defined as at least two standard deviations above normal. The study

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

Mon, 15 Jun 2026 07:00:00 -0400

SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design

BLA supportive manufacturing strategy includes flexible process validation, including reduced PPQ manufacturing batches

SUNRISE-FA 2 initiation on track for Q2 2026, with first patient expected to be enrolled by end of June

Company to host webcast today at 8:00 AM ET

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

Mon, 15 Jun 2026 07:00:00 -0400

SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design

BLA supportive manufacturing strategy includes flexible process validation, including reduced PPQ manufacturing batches

SUNRISE-FA 2 initiation on track for Q2 2026, with first patient expected to be enrolled by end of June

Company to host webcast today at 8:00 AM ET

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

Mon, 15 Jun 2026 07:00:00 -0400

SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design

BLA supportive manufacturing strategy includes flexible process validation, including reduced PPQ manufacturing batches

SUNRISE-FA 2 initiation on track for Q2 2026, with first patient expected to be enrolled by end of June

Company to host webcast today at 8:00 AM ET

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

Mon, 15 Jun 2026 07:00:00 -0400

SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design

BLA supportive manufacturing strategy includes flexible process validation, including reduced PPQ manufacturing batches

SUNRISE-FA 2 initiation on track for Q2 2026, with first patient expected to be enrolled by end of June

Company to host webcast today at 8:00 AM ET

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

Mon, 15 Jun 2026 07:00:00 -0400

SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design

BLA supportive manufacturing strategy includes flexible process validation, including reduced PPQ manufacturing batches

SUNRISE-FA 2 initiation on track for Q2 2026, with first patient expected to be enrolled by end of June

Company to host webcast today at 8:00 AM ET

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

Mon, 15 Jun 2026 07:00:00 -0400

SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design

BLA supportive manufacturing strategy includes flexible process validation, including reduced PPQ manufacturing batches

SUNRISE-FA 2 initiation on track for Q2 2026, with first patient expected to be enrolled by end of June

Company to host webcast today at 8:00 AM ET

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

Mon, 15 Jun 2026 07:00:00 -0400

SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design

BLA supportive manufacturing strategy includes flexible process validation, including reduced PPQ manufacturing batches

SUNRISE-FA 2 initiation on track for Q2 2026, with first patient expected to be enrolled by end of June

Company to host webcast today at 8:00 AM ET

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

Mon, 15 Jun 2026 07:00:00 -0400

SUNRISE-FA 2 study parameters include LVMI primary endpoint, 6-month topline efficacy analysis, inclusion criteria focused on abnormal baseline LVMI and open-label trial design

BLA supportive manufacturing strategy includes flexible process validation, including reduced PPQ manufacturing batches

SUNRISE-FA 2 initiation on track for Q2 2026, with first patient expected to be enrolled by end of June

Company to host webcast today at 8:00 AM ET

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering

Form 4 Lexeo Therapeutics, Inc. For: May 18 Filed by: Townsend Richard Nolan

Wed, 20 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260520/26528857.html

Form 4 Lexeo Therapeutics, Inc. For: May 18 Filed by: Townsend Richard Nolan

Wed, 20 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260520/26528857.html

Form 4 Lexeo Therapeutics, Inc. For: May 18 Filed by: Otero Jose Manuel

Wed, 20 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260520/26528868.html